CD19 t-haNK- IV Administration

BIOLOGICAL2 trials

Sponsors

ImmunityBio, Inc.

Conditions

Relapsed B-Cell Non Hodgkin LymphomaRelapsed B-Cell Non-Hodgkin Lymphoma

Phase 2

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

RecruitingNCT07125872

ImmunityBio, Inc.Relapsed B-Cell Non Hodgkin Lymphoma

Start: 2025-11-11End: 2028-05-25Target: 20Updated: 2026-05-04

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Not yet recruitingNCT07477366

ImmunityBio, Inc.Relapsed B-Cell Non-Hodgkin Lymphoma

Start: 2026-04-01End: 2028-12-01Target: 20Updated: 2026-03-17